N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
N-(2-PHENYL-4-PIPERIDINYLBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS
申请人:AstraZeneca AB
公开号:EP1137637A1
公开(公告)日:2001-10-04
US6403601B1
申请人:——
公开号:US6403601B1
公开(公告)日:2002-06-11
[EN] N-(2-PHENYL-4-PIPERIDINYBUTYL)-5,6,7,8-TETRAHYDRO-1-NAPHTHALENECARBOXAMIDES AND THEIR USE AS NEUROKININ 1 (NK1) AND/OR NEUROKININ 2 (NK2) RECEPTOR ANTAGONISTS<br/>[FR] N-(2-PHENYLE-4-PIPERIDINYBUTYLE)-5,6,7,8-TETRAHYDRO-1-NAPTHALENE CARBOXAMIDES ET LEUR UTILISATION COMME ANTAGONISTES DES RECEPTEURS DE LA NEUROKININE 1 (NK1) ET/OU DE LA NEUROKININE 2 (NK2)
申请人:ASTRAZENECA UK LTD
公开号:WO2000034243A1
公开(公告)日:2000-06-15
Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.
NOVEL BICYCLIC-CARBOXAMIDE COMPOUNDS USEFUL AS PESTICIDES
申请人:[en]SYNGENTA CROP PROTECTION AG
公开号:WO2024126650A1
公开(公告)日:2024-06-20
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers, or N-oxides of those compounds, can be used as insecticides.
N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthalenecarboxamides and their use as neurokinin 1 (NK1) and/or neurokinin 2 (NK2) receptor antagonists
申请人:Astrazeneca AB
公开号:US06403601B1
公开(公告)日:2002-06-11
Compounds of formula (I), wherein R2 is a 5,6,7,8-tetrahydronaphth-1-yl group which may be substituted (the remaining groups defined herein), and pharmaceutical compositions containing the compounds and methods of using the compounds in the treatment of a condition where antagonism of the NK1 and/or NK2 receptors is beneficial.